Skip to main content

Copanlisib Side Effects

Medically reviewed by Last updated on Aug 26, 2023.

Applies to copanlisib: intravenous powder for solution.

Serious side effects of Copanlisib

Along with its needed effects, copanlisib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking copanlisib:

More common

Other side effects of Copanlisib

Some side effects of copanlisib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to copanlisib: intravenous powder for injection.


The most common (20% or greater) adverse reactions were hyperglycemia, decreased hemoglobin, decreased lymphocyte count, decreased white blood cell count, decreased platelet count, decreased neutrophil count, hypertriglyceridemia, hypophosphatemia, diarrhea, decreased general strength and energy, hypertension, leukopenia, neutropenia, nausea, hyperuricemia, thrombocytopenia, lower respiratory tract infections, and increased serum lipase.[Ref]


Very common (10% or more): Hyperglycemia (95%)[Ref]


Very common (10% or more): Decreased hemoglobin (78%), decreased lymphocyte count (78%), decreased white blood cell count (71%), decreased platelet count (65%), decreased neutrophil count (63%), leukopenia (36%), neutropenia/febrile neutropenia (32%), thrombocytopenia (22%)[Ref]


Very common (10% or more): Hypertriglyceridemia (58%), hypophosphatemia (44%), increased serum lipase (21%)[Ref]


Very common (10% or more): Diarrhea (36%), nausea (26%), stomatitis/oral pain/oropharyngeal erosion and ulcer (14%), vomiting (13%)[Ref]


Very common (10% or more): Decreased general strength and energy/fatigue/asthenia (36%)

Common (1% to 10%): Mucosal inflammation[Ref]


Very common (10% or more): Hyperuricemia (25%)[Ref]


Very common (10% or more): Lower respiratory tract infections (21%)

Common (1% to 10%): Pneumonitis[Ref]

Nervous system

Common (1% to 10%): Paresthesia, dysesthesia[Ref]


Very common (10% or more): Rash/exfoliative skin reactions (15%)[Ref]


Very common (10% or more): Hypertension/secondary hypertension (13%)[Ref]


1. (2017) "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.